Cosciens Biopharma Files Routine 6-K Report
Ticker: CSCIF · Form: 6-K · Filed: Nov 12, 2024 · CIK: 1113423
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer, company-update
TL;DR
Cosciens Biopharma (formerly Aeterna Zentaris) filed its monthly 6-K report on Nov 12, 2024. Standard compliance filing.
AI Summary
Cosciens Biopharma Inc. filed a Form 6-K on November 12, 2024, reporting for the month of November 2024. The company, formerly known as Aeterna Zentaris Inc., is a pharmaceutical preparations company based in Toronto, Canada. This filing is a routine report for foreign private issuers.
Why It Matters
This filing indicates ongoing reporting compliance for Cosciens Biopharma Inc., a foreign private issuer, which is important for investors tracking the company's regulatory adherence.
Risk Assessment
Risk Level: low — This is a routine administrative filing and does not contain new material financial or operational information.
Key Players & Entities
- COSCIENS Biopharma Inc. (company) — Filer
- Aeterna Zentaris Inc. (company) — Former company name
- Norton Rose Fulbright Canada, LLP (company) — Legal counsel/address provider
- 20241112 (date) — Filing date
FAQ
What is the primary purpose of this Form 6-K filing?
The Form 6-K is a Report of Foreign Private Issuer filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, for the month of November 2024.
What is the current name of the company filing this report?
The current name of the company is COSCIENS Biopharma Inc.
What were the company's previous names?
The company was formerly known as Aeterna Zentaris Inc. and AETERNA LABORATORIES INC.
Where is the company's principal executive office located?
The company's principal executive office is located at c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7.
Does the company file annual reports under Form 20-F or Form 40-F?
The registrant indicates it files annual reports under cover of Form 20-F.
Filing Stats: 869 words · 3 min read · ~3 pages · Grade level 15.9 · Accepted 2024-11-12 07:30:15
Filing Documents
- form6-k.htm (6-K) — 31KB
- ex99-1.htm (EX-99.1) — 62KB
- ex_001.jpg (GRAPHIC) — 16KB
- 0001493152-24-044513.txt ( ) — 117KB
forward-looking statements
forward-looking statements. Forward-looking synergies as well as the assets, cost structure, financial position, cash flows and growth prospects of the combined company. Risks and factors that could cause actual results or outcomes to differ materially from expectations include, among others, the following: the Company’s patented technologies and value-driving products, and development thereof; the extraction, production and commercialization of active ingredients from natural sources and our ability to successfully market related products; the successful development and marketing of our oat-based pipeline products, including oat-beta glucan, avenanthramides and beta glucan from yeast, as well as such products’ capability to address unmet needs within the nutraceuticals markets; Macrilen® (macimorelin) and the Company’s plans in respect of same, including commercialization and clinical programs as well as in respect of the top line data from the DETECT-trial; the Company’s business strategy; the strategic decision to sunset the Company’s Amyotrophic Lateral Sclerosis (ALS) program; the Company’s positioning in its target markets; the Company’s ability to accelerate the scale-up of PGX Technology towards commercial levels; expectations for completion of the Company’s Edmonton facility and Natex Termitz facility; pre-clinical and clinical studies and trials and their expected timing and results, including the potential to bring certain products to market following such studies and trials; the ability of our pharmaceutical therapeutic assets to address unmet medical needs across a number of indications; management’s assumptions, estimates and judgements; liquidity and capital resources; adequacy of our financial resources to finance operations and e